Register

HR+   

Questions discussed in this category

Would you offer capivasertib+fulvestrant in a patient with metastatic HR+ HER2 negative breast cancer with PTEN mutation who has progressed on fulvestrant plus ribociclib?
3 Answers available
How do you define PIK3CA/AKT/PTEN alteration for capivasertib use?
Patient with stage IV ER+PR+Her2- breast cancer progressed after CDK4/6 inhibitor+AI and then on Elacestrant. Guardant 360 showed ESR1 mutation and PI...
2 Answers available
What disease characteristics will guide your choice of alpelisib plus fulvestrant (per SOLAR-1) versus capivasertib plus fulvestrant (per CAPItello-291) in Pik3ca mutated advanced ER+/HER2- breast cancer after progression on 1L ET regimen, given both are now approved in this population?
3 Answers available
Are there scenarios where you would consider use of capivasertib for non-AKT pathway altered patients given the efficacy seen in the overall treatment population of the CAPItello-291 trial?
PFS curves appear similar between the AKT-altered vs overall study population in the trial publication. Is there any additional information available ...
3 Answers available
Would you use sequential CDK 4/6 inhibitors in HR-positive metastatic breast CA in successive lines of therapy?
In MONALEESA-2, it appears ~22% of those in the ribcociclib group received a subsequent CDK4/6 inhibitor. What was the rationale and could this have i...
5 Answers available
How strict are you about adhering to the eligibility criteria required for entry onto the OlympiA trial in considering a year of adjuvant olaparib as adjuvant therapy for BRCA mutated, node positive, ER positive breast cancer?
If a patient had a CPS-EG of 2 after neoadjuvant therapy, would you offer that patient olaparib even though she wouldn't have met entry criteria? If t...
2 Answers available
In patients with both ESR1 and PIK3CA mutations who have progressed on AI+CDK4/6 inhibitor, how are you deciding the treatment/sequence of next-line therapies?
Role of capivasertib vs SERD? What factors help you decide?
4 Answers available
How would you treat a newly diagnosed male with metastatic HR+ breast cancer?
Do you give first-line CDK 4/6 inhibitors with Tamoxifen or Aromatase Inhibitor (+/- GnRH analog)?
1 Answer available
How should we think about endocrine resistance in patients with inherited germline mutations such as BRCA, CHEK2, etc.?
Should these patients have a different threshold for utilizing a CDK4/6 inhibitor in the front line metastatic or as part of adjuvant therapy, or SERD...
1 Answer available
When would you feel comfortable with patients who have a history of hormone-receptor positive breast cancer using hormonal IUDs (e.g. Mirena)?
2 Answers available
How would you treat a patient with symptomatic and rapidly progressing metastatic HR+, HER2 low breast cancer with PIK3CA WT, ESR1 mutated, TMB high after progression on CDK 4/6 inhibitor, a taxane, and T-DXd?
1 Answer available
Do you recommend the use of elacestrant after prior fulvestrant in metastatic hormone positive breast cancer?
1 Answer available
For a patient with metastatic HR positive breast cancer presenting with spinal cord compression but no visceral metastases, what is your recommended first line systemic therapy?
Would you start with endocrine therapy + CDK 4/6 inhibitor or a chemotherapy based regimen?
2 Answers available
What is your preferred first line therapy for metastatic HR+ inflammatory breast cancer?
1 Answer available
Would you offer definitive local therapy to a patient with ER/PR+, Her2 neg breast cancer with oligometastatic disease that responded well to CDK 4/6 inhibitor +AI, despite NRG-BR002 results?
Young healthy patient, ER/PR positive HER2 negative right breast cancer with a synchronous single site of oligometastatic disease in the right 4th rib...
2 Answers available
How do you manage adjuvant endocrine therapy for microinvasive HR-positive disease measuring >=1mm in extension?
1 Answer available
Is there any role for elacestrant in patient who have received prior fulvestrant if they have ESR1 mutation?
3 Answers available
How do you approach treatment of patients with metastatic HR+ breast cancer with detection of ESR1 mutation after initiation of an AI and CDK4/6 Inhibitor?
How does data from PADA-1 and EMERALD trials impact your decision-making?  
3 Answers available
What is your cut off on ER percent positivity to treat breast cancer as functional triple negative cancer?
Do you take PR percent into account?
2 Answers available
How do you decide whether to offer tamoxifen or OFS + AI in premenopausal patients with metastatic ER+ HER2+ breast cancer as your endocrine therapy?
What data may support the routine escalation of endocrine therapy? Should HER2 therapy be prioritized instead?
1 Answer available
Would you consider reserving CDK4/6 Inhibitors as second line treatment in patients with advanced HR+ HER2 negative breast cancer given SONIA and PALMIRA trial results?
2 Answers available
Would you consider AI alone over CDK4/6 inhibitor combinations in older patients with breast cancer considering the subgroup analyses from MONALEESA-2 suggest less benefit in patients over 65?
4 Answers available
Are you offering chemotherapy for premenopausal patients with HR+ node-positive breast CA with OncoType dx scores in the intermediate range of 11-25?
How do you reconcile the apparent benefit in all patients in this group as opposed to the differential effects in premenopausal HR+ node-negative pati...
3 Answers available
What is your approach to treatment in hormone receptor positive, HER2 negative (0 IHC) metastatic breast cancer with ERBB2 gene amplification after progression on AI and fulvestrant CDK4/6i with visceral crisis?
1 Answer available
How long would you continue trastuzumab and pertuzumab in a patient with ER+ HER2+ breast cancer with initially osseous involvement treated with ACT-HP and is now in CR by PET for >2 years?
1 Answer available
Do you feel comfortable using ribociclib in a patient with metastatic ER+/HER2+ breast cancer who has borderline systolic heart failure from previous HER2 based treatment?
Are you more worried about QT prolongation in this subset of patients?
1 Answer available
What first line therapy would you give a premenopausal patient with HER-2 positive and ER positive metastatic breast cancer with visceral organ involvement?
Add OFS with endocrine therapy plus Taxane-HP combo? What taxane is preferred? 
1 Answer available
In patients who have received neoadjuvant endocrine therapy for localized ER/PR+, HER2 negative breast cancer, how do you decide which patients to offer adjuvant chemotherapy to?
What type of adjuvant chemotherapy would you offer? Would clinically positive lymph nodes or residual disease at the time of surgery change your decis...
1 Answer available
Which chemotherapy is preferred between TC and AC-T in a young patient with ER+/PR+/HER2- node negative breast cancer, intermediate grade, with high OncoType score? 
3 Answers available
How long would you recommend a woman with HR+ node-positive breast cancer treated with surgery and chemotherapy during pregnancy can breastfeed, prior to starting adjuvant endocrine therapy?
2 Answers available
What alternate neo-adjuvant backbone chemotherapy would you recommend in a patient with ER+ HER2+ clinical stage II breast CA with severe pan-colitis following a cycle of TCHP with docetaxel?
3 Answers available
Would you recommend adjuvant abemaciclib for ER+ HER2 neg inflammatory breast cancer who do not achieve pCR with neoadjuvant chemotherapy?
MONARCHE added an amendment to their protocol to exclude inflammatory breast cancer so they technically would not qualify for the trial though it's ha...
2 Answers available
Would you still obtain Ki-67 prior to use of adjuvant abemaciclib in a patient who has otherwise met MonarchE treatment criteria, such as 1-3 positive LNs, grade 3 and/or tumor >5 cm?
Patient is pre-menopausal and has cT3cN1, grade 2, ER positive, Her 2 negative IDC. Metastatic disease to axillary LNs was biopsy-proven. Patient was ...
1 Answer available
How would you treat a post-menopausal woman with recurrent breast cancer, T1bN0 HR+ (ER/PR > 90%), HER2- s/p lumpectomy and adjuvant RT with low oncotype of 6?
Is deferring chemotherapy based on low oncotype acceptable in setting of recurrence?    Would you recommend using a different AI, Tam...
2 Answers available
How would you approach adjuvant systemic therapy in a HR+ premenopausal patient over the age of 50?
Would you recommend using chemotherapy based on RxPonder regardless of Oncotype score in a premenopausal patient? Or would you hold chemotherapy since...
2 Answers available
Will you recommend abemaciclib in combination with standard adjuvant endocrine therapy in patients with high risk hormone receptor positive, HER2- early breast cancer?
With the recent announcement that the phase 3 MonarchE trial met its primary endpoint. 
3 Answers available
How would you treat a newly metastatic ER+ PR+ HER2+ triple positive breast cancer with diffuse symptomatic disease and severe neuropathy from prior adjuvant paclitaxel?
1 Answer available
In patients with metastatic hormone receptor-positive, HER2-low breast cancer, how many and which lines of therapy would you recommend prior to using trastuzumab deruxtecan?
Are there any circumstances where use of T-DXd would supercede the use of CDK4/6 inhibitors or other non-chemotherapeutic options (PIK3CA etc?)
9 Answers available
In a patient with ER+/HER2+ breast cancer with significant residual disease post neoadjuvant TCHP, is there a role of using CDK4/6i in the adjuvant setting with T-DM1?
1 Answer available
Would you offer adjuvant olaparib to a male patient with HR+, HER2- T2N0 breast cancer with a BRCA2 germline mutation following mastectomy who is not a candidate for adjuvant chemotherapy?
2 Answers available
Would you give adjuvant endocrine therapy to a premenopausal woman with early stage node positive breast cancer that was ER negative, PR positive (60%) and HER2 positive?
She achieved PCR with NAC with TCHP and is now on adjuvant HP. 
2 Answers available
Do you use Oncotype to predict chemo benefit on all localized HR+ patients per TAILORx criteria or do you use your judgement and skip it in T1b-c grade 1 or grade 2 tumors?
3 Answers available
How do you approach adjuvant therapy to minimize cardiotoxicity in early stage node negative HER2+ HR+ breast cancer with history of chest wall radiation and previous cardiotoxic agents for Hodgkin Lymphoma?
1 Answer available
Would you offer adjuvant Abemciclib to ER positive HER2 negative with 1 LN positive, Ki-67 >20%, and low Oncotype?
Tumor 3 cm, grade 2 with Ki-67 25%
1 Answer available
How do you interpret the EBCTCG meta-analysis analyzing the magnitude of benefit of anthracyclines in early stage ER+ breast cancer?
How do you reconcile these findings with the ABC trials?
3 Answers available
For patients with prior HR+HER2- localized breast cancer currently receiving adjuvant endocrine therapy, is there a time period in which you would no longer recommend adding adjuvant abemaciclib?
(Assuming they meet MonarchE criteria) For example, if the patient is in year 2, 3, 4, or 5 of adjuvant endocrine therapy versus 9 months out, would ...
3 Answers available
Do you prefer CDK 4/6 inhibitor or PARP inhibitor as first line treatment in a patient with HR+/HER2 neg relapsed/metastatic BRCA positive breast cancer who had previous adjuvant chemotherapy and developed metastatic recurrence while on AI?
6 Answers available
What adjuvant treatment approach would you choose for a premenopausal woman with lymph node positive poorly differentiated metaplastic breast cancer that is ER low+, PR+, HER2 negative?
Is there a role for KEYNOTE-522 since ER + metaplastic breast cancer have similar behavior to triple negative metaplastic breast cancer? 
1 Answer available
What dose and formulation of GnRH agonist do you use for ovarian suppression in young breast cancer patients?
Do you use a q4 week or q12 week formulation? If you use both in your practice, what factors into your decision making for either one?
1 Answer available
Would you offer OFS/AI alone or with the addition of chemotherapy in a premenopausal female with ER+/PR+ breast cancer with microscopic LN involvement and an OncoTypeDx score <11?
1 Answer available
In what scenarios do you consider omitting adjuvant endocrine therapy after lumpectomy for DCIS?
How strongly would you recommend it for a grade 1, < 1 cm DCIS?
2 Answers available
Do you modify your choice of systemic therapy for localized early stage ER+/PR+ HER2- breast if Mammaprint shows basal subtype?
2 Answers available
Would you offer endocrine therapy to a patient who developed a new contralateral pT1b pN0 ER/PR+ HER2- breast IDC 1 year after coming off 10 years of anastrozole for prior invasive breast cancer?
2 Answers available
Do you utilize Mammaprint testing to determine whether or not to offer neoadjuvant chemotherapy for high risk ER+ breast cancer?
2 Answers available
How do you select systemic therapy for recurrent HR+ HER2 negative breast cancer in the bones in a premenopausal woman within a year of starting adjuvant AI with OFS plus abemaciclib and zoledronic acid?
She had been initially treated with neoadjuvant AC-T followed by BCS and RT with high burden residual disease in the breast and lymph nodes.
1 Answer available
How do you approach systemic treatment for intracranial only brain metastases for ER positive, PR negative, HER2 negative breast cancer after stereotactic radiosurgery for brain metastases with negative PET imaging?
1 Answer available
Do you use platinum therapy in BRCA1 mutated patients with ER/PR positive disease receiving neoadjuvant chemotherapy?
2 Answers available
How would you continue management of a patient with clinical stage II cN+ HR+ HER2+IDC with grade 3 diarrhea after 1 cycle of neoadjuvant TCHP?
2 Answers available
How do you decide among approved CDK4/6 inhibitors for first line treatment of patients with metastatic HR+ breast cancer now that OS analyses are available in MONALEESA-2, MONARCH-3 and PALOMA-2?
How do you compare their efficacy overall?
5 Answers available
How do you use baby tam, low dose tamoxifen, in your practice?
1 Answer available
How does your treatment approach vary in patients with HR+/HER2- breast cancer presenting with CNS metastases?
While rare, these patients were excluded from all frontline CDK4/6 inhibitor trials. Is there any data on the efficacy of ribociclib in the CNS or abi...
2 Answers available
How would you manage subsequent treatment for a patient with metastatic ER+HER2- breast cancer that develops pneumonitis on a CDK4/6 inhibitor but had an excellent response to therapy?
Would you change to a different CDK4/6 inhibitor or avoid the entire class of drugs?
2 Answers available
How do you select your first-line endocrine therapy to accompany CDK4/6 inhibitor in metastatic HR+ breast cancer?
Results with fulvestrant and letrozole backbone in MONALEESA and MONARCH trials seem comparable, but PALOMA data is somewhat mixed. How do these trial...
1 Answer available
Do you think about CDK4/6 inhibitor selection differently in a patient with de novo rather than recurrent metastatic disease?
Subgroup analyses in MONALEESA-2 suggest more benefit in de novo treatment naive patients, which is in contrast to MONARCH-3 data presented at ESMO 20...
2 Answers available
Would you treat a Stage I ER/PR positive HER2 negative breast cancer differently if it is associated with Lynch syndrome?
3 Answers available
How would you approach a young patient with a prior ER+ HER2- breast CA now local recurrence that now has Her2 positive disease?
If a patient previously received taxane-based chemotherapy for the initial cancer, is additional chemotherapy recommended or can HER2-directed and hor...
1 Answer available
Does the magnitude of OncoType recurrence score above 26 inform decision between TC and AC/T in ER+ HER2- 1-3 node positive, postmenopausal patients with breast cancer?
Is the marginal advantage of AC/T in 1-3 node positive outweighed by toxicity such as risk of cardiotoxicity and leukemia, regardless of RS?
1 Answer available
How far can you dose reduce abemaciclib for a patient who is having toxicity at starting doses?
Can you use 50 mg BID if intolerant to 150 mg and 100 mg dosing? Any tips for side effect management to help patients stay on full duration?
6 Answers available
Does the magnitude of benefit with 2 years of adjuvant abemaciclib outweigh side effects, given that many patients will receive CDK 4/6 inhibitors at breast cancer recurrence, precluding OS benefits?
MonarchE shows statistically significant improvement in IDFS and DRFS, but the magnitude of absolute benefit is modest (3-year IDFS and DRFS rates = 5...
6 Answers available
Do you prefer using an anthracycline or non-anthracycline adjuvant regimen in BRCA+ premenopausal patients with localized HR+ breast cancer?
Assuming chemotherapy is indicated because of the Oncotype score. 
1 Answer available
Will you offer adjuvant abemaciclib to breast cancer patients with high Ki-67 who are unable to receive either neoadjuvant or adjuvant chemotherapy due to comorbidities or who decline chemotherapy?
Majority of patients on MonarchE received neoadjuvant/adjuvant chemo.  Does the availability of abemaciclib impact your decision to offer chemo ...
4 Answers available
What adjuvant therapy would you offer an elderly but healthy patient with T2N1 HR+ HER2+ breast cancer who is not willing to receive cytotoxic chemotherapy?
1 Answer available
How do you plan to use adjuvant denosumab in patients with hormone positive breast cancer given the survival advantage seen in the ABCSG-18 trial?
Do you look into their stage/risk to decide? Since patients can experience bone loss after stopping denosumab, how do you plan to discontinue?
1 Answer available
Do you utilize genomic testing, such as OncoType or Breast Cancer Index, in HR positive breast cancer to make recommendations regarding the duration of endocrine therapy?
3 Answers available
Do you need to wait for estradiol and FSH levels to normalize before you can switch from tamoxifen to an AI for a pre-menopausal woman with ER+ breast cancer?
What steps should be taken when switching premenopausal women from tamoxifen to AI? In this case, the change is due to newly discovered endometrial th...
1 Answer available
Would you consider adjuvant endocrine therapy for DCIS in a patient who received bilateral nipple-sparing mastectomies?
Endocrine therapy is usually not indicated for DCIS s/p bilateral mastectomy, but would the fact that residual tissue (nipple-sparing) alter your deci...
2 Answers available
For premenopausal patients with ER+ PR+ HER2 negative breast cancer and lymph node micrometastases, would recurrence score be most appropriately interpreted based on TAILORx data, given such patients were excluded from RxPONDER?
1 Answer available
What is optimal endocrine therapy in a young, premenopausal women with ER/PR positive oligometastic breast cancer successfully treated with curative intent neoadjuvant chemo followed by surgery+RT to skeletal oligomet?
Would you include a CDK4/6 inhibitor knowing the patient doesn't meet criteria of monarchE trial but still is Stage IV?
1 Answer available
If you have a high risk HR+, BRCA+ breast cancer patient who qualifies for adjuvant olaparib and abemaciclib, which one would you give and why?
Would you ever consider using these in sequence?
4 Answers available
What is your approach to adjuvant hormone therapy for HR+ breast cancer in post-menopausal women with pre-existing osteoporosis?
Would you consider omitting treatment if small tumor and early stage? Or would you use tamoxifen?
2 Answers available
How would you approach a locally recurrent HER2 positive breast cancer patient previously treated with TCHP, lumpectomy, and a year of adjuvant TDM-1?
Patient was initially ER positive, HER2 positive. Currently she is on letrozole. Recurrence is ER/PR negative and HER2 positive and developed almost 2...
1 Answer available
Would you be comfortable starting tamoxifen for a HR+ breast cancer patient with a history of early stage endometrial cancer treated via hysterectomy?
1 Answer available
Would you offer adjuvant chemotherapy to a post menopausal woman with T1-T3 primary tumor with 4 positive axillary LNs and OncotypeDX score less than 15?
2 Answers available
In which situations do you offer neoadjuvant chemotherapy for a nodal recurrence alone of ER/PR positive, HER2 negative breast cancer?
Patient is young and reoccurrence is one year after initial diagnosis of T1cN0 ER/PR positive, HER2-negative breast cancer treated with mastectomy, bu...
1 Answer available
Do you plan to offer adjuvant olaparib to all gBRCA+ breast cancer whether TNBC or HR+?
In subset analyses of OlympiA there seems to be smaller magnitude of benefit among HR+ patients. In your opinion, should adjuvant olabarib be offered ...
3 Answers available
How would you treat a post-menopausal woman found to have a node-negative ipsilateral HR+ breast cancer recurrence with pectoral muscle invasion following a prior mastectomy, radiation, and AI therapy completed > 5 years ago? 
1 Answer available
What is your approach to chemoprevention for HR+ DCIS in the ipsilateral breast in a patient who already completed 7 years of an AI for a prior HR+ invasive breast cancer?
Patient underwent mastectomy for DCIS in the setting of previous lumpectomy and adjuvant radiation for the invasive breast cancer. 
2 Answers available
How and on which specimens will you perform Ki-67 testing in newly diagnosed breast cancer?
Should this be sent on initial biopsy or on surgical pathology? What if an initially high risk patient has good risk findings post-operatively?What ha...
4 Answers available
How do you incorporate oncotype Dx recurrence score when planning adjuvant CDK 4/6 inhibitor for high risk early stage HR+ breast cancer?
1 Answer available
Would you offer adjuvant abemaciclib to node-positive patients with low ER expression?
For instance, ER/PR >1% but <10% and Ki67 >50%
3 Answers available
How do you approach treatment in premenopausal patients who develop a contralateral HR+ breast cancer while already on tamoxifen and ovarian function suppression?
How would you manage endocrine therapy 7 years after the original ER+/PR+/HER2- IDC, while on adjuvant tamoxifen/OFS develops a contralateral ER+/PR+/...
2 Answers available
How do you view the use of adjuvant CDK4/6 inhibitors overall given discordant results between MonarchE and PALLAS?
Are there factors to explain why MonarchE was a positive study and PALLAS was not? 
4 Answers available
Would you offer adjuvant abemaciclib + an aromatase inhibitor to a patient with a local HR+HER- breast cancer reoccurrence while on tamoxifen that meets high-risk criteria?
High-risk criteria meaning >4 positive nodes and Ki67 >20%
3 Answers available
Is there a clinically significant increased risk of venous thromboembolism with the use of fulvestrant for metastatic HR+ breast cancer?
In a patient with a history of VTE (now off anticoagulants), is it safe to administer fulvestrant?
1 Answer available
Would you use OncoType Dx to guide adjuvant therapy recommendations in the context of locally recurrent, node-negative, ER+ breast cancer previously treated with endocrine therapy alone?
No oncotype was sent on the original breast cancer.
1 Answer available
Does a very high Oncotype score influence your approach to adjuvant treatment in a patient with ER positive breast cancer?
For example, does a higher recurrence score influence your choice of TC versus AC-T?  Or your choice to add ovarian suppression to a premenopausa...
2 Answers available
Is there a role for extended adjuvant neratinib with pCR after neoadjuvant chemotherapy in triple positive breast cancer?
1 Answer available
What is the optimal sequence of systemic therapy for a patient with HR+, gBRCA mutated metastatic breast cancer?
1 Answer available
Would you use aspirin 81 mg for VTE prophylaxis in patients on adjuvant tamoxifen/SERMs?
Is there data that it actually helps?
1 Answer available
Would you treat a postmenopausal women with high grade T2N0 ER-, PR+, HER2- invasive ductal carcinoma with upfront surgery or neoadjuvant chemotherapy?
ER <1%; PR 45%, Her2 negative by IHC and FISH. Grade 3, Ki67: 80%.
1 Answer available
How do you manage HR+HER2 negative ILC metastatic recurrence in a post-menopausal woman with extensive GI involvement complicated by a small bowel obstruction?
Patient was on tamoxifen when progression occurred; unable to tolerate adjuvant AI.
1 Answer available
In light of RxPonder results for postmenopausal women with early stage node positive HR+HER2- breast cancer, when is there a role for full axillary LN dissection to confirm degree of nodal involvement and when would sentinel LN evaluation be sufficient?
How would this affect adjuvant radiation plan in breast conservation therapy patients and mastectomy patients?
1 Answer available
How would you manage adjuvant endocrine therapy for a postmenopausal patient with early stage HR+ breast CA who develops an ischemic CVA on an AI?
Presuming that work-up for cardioembolic sources is negative, how would you proceed?
1 Answer available
Do you discontinue anti-hormonal therapy if a high-risk ER+ HER2- localized breast cancer patient develops blood clots on anti-hormonal therapy?
How would you approach a patient who is intolerant of AI and develops thrombosis while on SERM?
3 Answers available
Would you consider using OncoType Dx testing in a patient with breast cancer if nodal evaluation is not performed?
No sentinel lymph node biopsy was performed 
1 Answer available
Would you use OncoType in a postmenopausal female with HR+/HER2- with LN involvement who clinically meets RxPONDER criteria of 1-3 LN to guide the use of neoadjuvant chemotherapy?
How would the use of Oncotype guide your management in the neoadjuvant setting?
2 Answers available
Would you modify the dose of aromatase inhibitors or selective estrogen receptor modulators in patients who have a history of gastric bypass or other malabsorptive conditions/surgeries?
1 Answer available
How would you manage a premenopausal female with cT2cN0 HR+/HER2-negative breast cancer who received neoadjuvant TC for high OncoType, had no pathologic response to therapy and upstaged to pT2N1 on surgery?
What adjuvant therapies would you recommend?
2 Answers available
What endocrine therapy would you recommend for a perimenopausal female with a low risk Oncotype, HR+, HER2-negative, SLNB negative breast cancer who is clinically postmenopausal but with FSH, LH and estradiol that are not in the postmenopausal range?
1 Answer available
Would you consider de-escalating treatment to endocrine therapy alone in a patient with prolonged NED on CDK 4/6 inhibitor + endocrine therapy?
Patient is on fulvestrant+CDK 4/6 inhibitor and with NED for 5 years. In which cases would you consider stopping CDK 4/6 inhibitor? 
1 Answer available
In cases in which Oncotype DX test is not available, how do you decide which patients with HR+ and Her2- breast cancer are candidates for adjuvant chemotherapy?
How would your management differ in pre- and post-menopausal females?
1 Answer available
Would you recommend extended adjuvant endocrine therapy if a patient tolerated 5 years thus far but Breast Cancer Index (BCI) shows a high risk of recurrence with low likelihood of benefit from extended therapy?
6 Answers available
What adjuvant treatment (if any) would you recommend for a post-menopausal patient with a borderline T1b (0.5 cm) grade 2 ER+/PR+/HER2 negative invasive lobular breast CA after bilateral mastectomies?
1 Answer available
How would you manage adjuvant therapy for a premenopausal female with a T1cN1mi breast IDC that is HR+ HER2 positive on biopsy, but HR+ HER2 negative on lumpectomy surgical specimen?
<40y/o female w/ initial biopsy showing G3 IDC with 80% ER+, 90% PR+, and HER2 positive (IHC 2+; 1.6 HER2/CEP17 ratio and 6.3 HER2 copies/nucleus.)...
2 Answers available
Do you give chemotherapy to women with clinical features of high risk ER+ breast cancer, but a low Oncotype DX score?
Is there an age cutoff below which you would offer adjuvant chemotherapy regardless of Oncotype results? (Example: A 35 y/o woman with T2N0, ER+, sen...
4 Answers available
How would you treat HR positive, HER2 positive metastatic breast cancer in patients with a borderline or poor performance status?
1 Answer available
How would you modify adjuvant therapy for a patient with ER+ HER2+ breast CA with no response to neoadjuvant TCHP and develops pneumonitis on adjuvant TDM-1?
Would you use trastuzumab/pertuzumab, trastuzumab followed by neratinib, or another strategy?
1 Answer available
What adjuvant systemic therapy would you offer to a healthy elderly woman with a 5mm, node negative, grade 2 HR+HER2+ invasive lobular carcinoma?
Would you choose to incorporate HER2-targeting agents, chemotherapy, endocrine therapy, or a mix of these?
4 Answers available
How would you manage a patient with early stage ER+ HER2+ breast CA who cannot receive definitive local therapy due to severe cardiopulmonary co-morbidities?
How would your plan differ if the patient could eventually receive mastectomy once co-morbidities improve?
1 Answer available
Would you consider adjuvant capecitabine in a premenopausal patient with HR-positive inflammatory breast cancer who had residual disease after neoadjuvant chemotherapy?
Masuda et al., NEJM 2017
1 Answer available
What is your approach for endocrine therapy in young women (<35 years old) with HR+/HER2+ breast CA with residual disease after TCHP who will start adjuvant T-DM1?
3 Answers available
What would you recommend as the next line treatment in a post-menopausal woman with hormone receptor positive, HER2 positive breast cancer, with progression on T-DM1 in combination with aromatase inhibitor?
1 Answer available
Which adjuvant chemotherapy regimen would you recommend for a peri-menopausal woman with synchronous stage IA primary breast tumors, one that is ER+HER2+ and the second ER+HER2-?
1 Answer available
If neoadjuvant therapy is indicated for luminal A breast cancer, when do you decide to use chemotherapy versus endocrine therapy?
Are there particular patient characteristics (e.g. age, ER%, Ki67, grade) that make you more likely to choose neoadjuvant endocrine therapy?
1 Answer available
How do you manage adjuvant endocrine therapy for pre-menopausal women with locally advanced, weakly positive ER/PR, HER2 negative breast cancer?
Would a pCR to neoadjuvant chemotherapy change your management? (ER <5%, PR <5%)
1 Answer available
For anatomic stage III ER/PR+ breast cancer treated upfront with surgery, how do you decide which adjuvant chemotherapy to offer?
Do features such as nodal involvement, Ki-67, degree of ER positivity, etc. change your management? Would you use any gene expression assays to help y...
1 Answer available
Would you give anthracycline chemotherapy to a patient with HR+, HER2 negative inflammatory breast cancer who has history of cardiomyopathy with LVH and moderately reduced EF but most recent echo shows improvement to normal or near normal ejection fraction?
If no anthracycline, what alternative regimen would you consider? 
5 Answers available
What is your approach to tamoxifen use in women who are unable to discontinue a strong CYP2D6 inhibitor and who are unable to use or tolerate an AI?
2 Answers available
How long would you keep a patient on endocrine/dual anti HER-2 therapy after resection of a late (>5 years) oligometastatic recurrence of ER+ HER2+ breast CA?
For patients who remain NED for years, when would you feel it's appropriate to hold therapy?
1 Answer available
How do recent RxPonder results affect your adjuvant therapy choice for premenopausal women with HR+/HER2 negative breast cancer with 1-3 positive LNs?
Would you consider an Oncotype or Mammaprint? Would your management change if the patient had 1-3 positive LNs on SLNBx (as opposed to ALND)?
1 Answer available
How do you manage endocrine therapy for a perimenopausal woman with ER+ breast CA?
The woman was on on a GnRH agonist + AI due to her premenopausal status at diagnosis and now wants to know if she continues to need the GnRH agonist.&...
1 Answer available
What is your neoadjuvant chemotherapy of choice in patients with ER+ breast CA who are receiving neoadjuvant therapy with goal to convert to BCS from mastectomy?
Would your decision for anthracycline change if the patient were elderly?
1 Answer available
How would you manage an elderly patient with clinical stage IIIC ER positive breast cancer who refuses surgery, chemo and radiation treatment and willing to take only oral medications?
2 Answers available
Do you give adjuvant chemotherapy/trastuzumab to a premenopausal woman with a pT1aN0 HR+, Her2+ breast cancer?
3 Answers available
What are your recommendations for post-menopausal patients who would fit into RxPonder trial criteria (HR+/HER2- breast cancer, 1-3 positive LNs) and have already started on adjuvant chemotherapy?
Would you send Oncotype during chemotherapy if not sent already? Would you stop adjuvant chemotherapy if a prior Oncotype was 25 or less?
2 Answers available
Would you give a HER2 targeted agent to a patient whose initial cancer was ER/PR positive, HER2 negative but now with metastatic disease that is ER positive, PR negative, HER2 2+, FISH equivocal?
Patient has progressed through prior lines of endocrine therapy. 
1 Answer available
How do the new RxPONDER results affect your choice of adjuvant therapy for postmenopausal women with HR+/HER2 negative breast cancer and 1-3 positive lymph nodes?
Would you send an Oncotype RS to determine the role of adjuvant chemotherapy and/or endocrine therapy?
1 Answer available
Would you use a PARP inhibitor in metastatic ER/PR positive breast cancer with somatic BRCA1 mutation but negative for germline mutation?
2 Answers available
How would you approach adjuvant therapy for a young post-menopausal woman with a grade 3 pT1a (5mm) node negative ER+/HER2- invasive ductal carcinoma?
 Would you consider gene profiling to determine need for chemotherapy?
2 Answers available
How would you approach diagnosis of residual ovarian tissue in a patient with ER positive breast cancer, history of BSO, and a rising estradiol level on tamoxifen?
1 Answer available
Will you use ovarian function suppression in lieu of chemotherapy in premenopausal patients with pN1 ER+ HER2- breast CA with OncoType RS <25?
Knowing the differential effect seen with menopausal status in RxPONDER, would you avoid chemotherapy or still offer chemotherapy, given that only 15....
1 Answer available
How would you manage a middle aged woman with history of severe alcoholic liver cirrhosis and a small node negative ER/PR positive, HER2 negative breast cancer?
How would you balance the competing risks of these two diagnoses in her treatment?
3 Answers available
How would you manage adjuvant treatment of a patient with ER+/PR+/HER2+ breast cancer and a small amount of residual disease (e.g. T1mi) following neoadjuvant TCHP?
Patient had a clinical T2N0 cancer at diagnosis, completed 6 cycles TCHP, and had 0.2mm residual disease with 80% cellularity, negative sentinel node.
4 Answers available
Based on the results of MonarchE, would you offer adjuvant abemaciclib for HR+ patients who do not achieve pCR after neoadjuvant chemotherapy?
Referring to a high risk patient with cT3N1 disease and ypT2N0 disease following neoadjuvant chemotherapy.
3 Answers available
Are you more inclined to offer adjuvant chemotherapy for a post-menopausal woman after lumpectomy for a small TNBC who has a concurrent metastatic ER+ breast CA?
Any difference in recommendations if the patient was asymptomatic from her metastatic ER+ disease? (eg bone mets)
1 Answer available
When would you offer ovarian suppression in addition to endocrine therapy for premenopausal women who omit adjuvant chemotherapy?
How do clinical risk and Mammaprint/Oncotype scores affect your decision?
1 Answer available
Is there any role for alpelisib in a patient who has triple positive breast cancer and an activating PIK3CA mutation?
1 Answer available
How would you counsel a patient with HR+, HER2- breast cancer with an OncotypeDx ROR score of 0 who is refusing endocrine therapy?
2 Answers available
Would you treat an ER/PR+ inflammatory breast cancer that is HER2 2+ by IHC but 5% positive by FISH as HER2 positive?
2 populations of cells with 95% negative by FISH (ratio 1.07) and 5% positive by FISH (ratio 10)
1 Answer available
What adjuvant therapy would you recommend for a premenopausal patient with ER/PR+, HER2 negative T2N0 breast cancer s/p mastectomy, low OncotypeDx score and in first trimester of pregnancy?
3 Answers available
Would you offer adjuvant chemotherapy for 1-3 node positive HR+, HER2 negative breast cancer with Mammaprint low risk to a young, pre-menopausal patient?
Based on MINDACT update from 2020, a 5% difference in DMFS for patients 50 years or younger was noted, favoring treatment with chemotherapy (93.6%; 95...
2 Answers available
How do you manage a breast cancer patient with discordance in hormone receptor status with IHC and Oncotype?
1 Answer available
Do you approach the treatment of post-lumpectomy DCIS which is only present within an intraductal papilloma differently, if it does not involve adjacent breast tissue?
What considerations do you take for post-lumpectomy radiation and endocrine therapy?
2 Answers available
Would you offer adjuvant chemotherapy to a premenopausal patient with ER/PR+ breast cancer, nodal micrometastasis, low OncotypeDx score but also BRCA2 carrier?
1 Answer available
How do you manage ovarian suppression for premenopausal patients with HR+/HER2 positive breast cancer?
Does lymph node positivity change your management?
1 Answer available
How would you manage a premenopausal woman with a poorly differentiated pT2 HR+/HER2- breast cancer and 3/3 SLNs with ITCs?
Would you consider ALND and /or XRT to axilla?
1 Answer available
How would you council a woman in her 50s with Stage I HR+/HER2- breast cancer with a high risk Mammaprint but intermediate OncotypeDx regarding adjuvant chemotherapy?
3 Answers available
Do you consider adjuvant chemotherapy for older women >75 years of age, with HR+ invasive ductal carcinoma and 3 positive LN however intermediate risk recurrence scores?
1 Answer available
Would you use a platinum containing regimen such as docetaxel + carboplatin for an aggressive ER+ breast cancer in a patient with a deleterious mutation in ATM?
1 Answer available
Would you treat a premenopausal woman with T2N0 ER-, PR+ (15-20%), HER2- breast cancer with neoadjuvant chemotherapy like a triple negative breast cancer?
6 Answers available
Would you offer chemotherapy to a postmenopausal woman with microinvasive ER/PR positive, Her2 negative invasive ductal carcinoma with a single lymph node metastasis and insufficient tissue for Oncotype testing? 
2 Answers available
Does ER+ status impact your choice of neoadjuvant systemic therapy in premenopausal women with cT2N0 HER2+ breast cancer?
How would your treatment change given pCR rates are reportedly much lower in triple positive patients?
3 Answers available
For a patient with isolated CNS recurrence of HR+HER2+ breast cancer after completion of adjuvant therapy, what, if any, systemic therapy would you start after completion of local therapy?
Of note, the patient received cytotoxic plus HER2 directed adjuvant therapy but declined endocrine therapy. 
2 Answers available
Is there a role for endocrine therapy alone in patients with metastatic HR+, HER2+ breast cancer after all HER2 directed therapies have been used?
1 Answer available
How would you approach adjuvant systemic therapy for a pT3N0(i+) HR+/HER2 negative breast cancer with an intermediate oncotype in a post-menopausal woman?
3 Answers available
How would you approach adjuvant endocrine therapy after excision of a hormone positive recurrence after mastectomy who finished 5 years of aromatase inhibitor for the same primary tumor?
1 Answer available
What other chemotherapy would you consider in a patient with high-risk node positive ER+, HER2- disease that developed pulmonary toxicity to paclitaxel and refuses any more taxanes?
She had already completed ddAC and two cycles of paclitaxel before the reaction.
1 Answer available
When do you choose a non-anthracycline containing regimen, such as docetaxel/cyclophosphamide, for patients with hormone receptor positive, HER2 negative breast cancer who warrant adjuvant chemotherapy?
Recent EBCTCG meta-analysis published in Lancet 4/2023. https://doi.org/10.1016/S0140-6736(23)00285-4
5 Answers available
What second line treatment would you choose for a post menopausal woman with HR+ HER2+ metastatic breast cancer with low burden disease treated with first line aromatase inhibitor and trastuzumab?
1 Answer available
Are pre-menopausal women on tamoxifen at risk for endometrial cancer?
Pre-menopausal women make progesterone and their menses are typically lighter on tamoxifen because it's a mild endometrial ER stimulant blocking their...
3 Answers available
Do you offer local treatment to the breast primary in patients with de novo oligometastatic hormone positive breast cancer?
How has your practice been impacted by the ECOG 2108 (Khan et al. ASCO 2020 Abst LBA2)? Are there sites or distribution of disease that prompt you to ...
1 Answer available
For a post-menopausal patient with a pT2N0 HR+/HER2- breast cancer at surgery after 4 months of neoadjuvant anastrozole with minimal clinical or pathologic response, would you utilize genomic testing to guide decision about adjuvant chemotherapy?
Would you test initial core biopsy (prior to neoadjuvant anastrozole) or surgical specimen? Any preference for Oncotype vs. Mammaprint?
1 Answer available
When would you consider fulvestrant + alpelisib in a postmenopausal patient who has HR+, PIK3CA mutant, metastatic breast cancer instead of initial CDK4/6 inhibitor therapy?
1 Answer available
How would you approach adjuvant treatment of an early stage HR+ HER2+ cancer if the patient had already been taking an aromatase inhibitor for a contra-lateral HR+ early stage breast cancer?
Interest in approach for elderly population especially 
3 Answers available
How do you approach continuing vs discontinuing ovarian suppression for high risk HR+ breast cancer when a patient becomes post-menopausal?
1 Answer available
How do you approach a stage IIIC triple positive IDC, s/p neoadjuvant TCH and P, lumpectomy, and ALND with significant residual disease at the time of surgery?
Would you recommend additional cytotoxic chemotherapy and/or switch her anti-Her therapy to T-DM1?
5 Answers available
How do you approach recommending tamoxifen in a premenopausal woman with Li Fraumeni syndrome and early stage low risk ER+ breast cancer?
How do you counsel regarding uterine sarcoma risk?
1 Answer available
What would you advise a breastfeeding woman with localized HR+ breast cancer in terms of risk of progression with breastfeeding prior to local therapy with surgery?
What timeframe would you suggest to stop breastfeeding? From affected breast or both breasts?
1 Answer available
How would you approach systemic therapy for a postmenopausal female with metastatic ER+/HER2+ breast cancer (liver/bone) who achieved a CR for 5 years on trastuzumab/pertuzumab and exemestane, with continued asymptomatic brain progression?
Asymptomatic brain progression despite CNS surgery and SRS x2 over the past 2 years.
1 Answer available
Can fulvestrant cause a tumor flare reaction in hormone receptor positive breast cancer?
1 Answer available
How would you approach a patient who responded to CDK4/6 inhibitor/endocrine therapy combination for metastatic HR+,HER2- breast cancer who now has disease progression which is biopsy proven TNBC?
Progression was observed only in the breast and required palliative mastectomy (T4b TNBC)
1 Answer available
How would you approach a postmenopausal woman with Stage I HR+,HER2- breast cancer who had a CVA while on tamoxifen?
3 Answers available
In the setting of COVID-19, would you perform a SLNB for a patient incidentally found to have microinvasive ER+ ILC in contralateral prophylactic mastectomy following neoadjuvant chemotherapy for a locally advanced triple positive breast cancer?
2 Answers available
Would you offer adjuvant therapy to a patient who underwent bilateral mastectomies for DCIS and was found to have isolated tumor cells on sentinel node biopsy?
She had had 4 prior biopsies. Would the fact that she received 2 months of neoadjuvant tamoxifen due to COVID change your approach?
1 Answer available
How do you approach use of tamoxifen in premenopausal patients who developed ovarian cysts while on therapy?
For example- do you have experience using a LHRH agonist along with tamoxifen?
1 Answer available
What pathologic response criteria do you use to determine the need for further adjuvant therapy in patients with breast cancer?
While the KATHERINE trial for HER2+ used path staging, CREATE-X for TNBC with capecitabine used the Japanese Breast Cancer Society response criteria. ...
1 Answer available
Would you consider adjuvant TDM-1 for a patient with HR+,HER2+ breast cancer with pCR in the breast but N1mic disease post neoaduvant chemotherapy?
N1mic - few isolated malignant cells in 1 axillary lymph node
1 Answer available
What would you use as adjuvant endocrine therapy for a patient who developed an invasive, hormone receptor positive breast cancer while on raloxifene for almost a decade prior?
Out of curiosity, I did tumor testing, and she does not have an activating ESR1 mutation.
1 Answer available
How would you approach a post-menopausal women with recurrent ER/PR+, HER2- breast cancer only in the axillary lymph nodes?
< 4 lymph nodes involved, initial diagnosis was 11 years ago when she was treated with mastectomy and adjuvant tamoxifen for 5 years.
5 Answers available
Would you consider using CDK 4/6 inhibitors in a patient with end stage renal disease (ESRD) along with an aromatase inhibitor?
If so, please describe your experience and dosing.
1 Answer available
How do you approach discussion of adjuvant chemotherapy for a T1b (0.5 cm) hormone positive breast cancer with high risk features and an Oncotype Score of 31?
1 Answer available
Would you consider OFS in a young patient (<35) with ER+ breast cancer who required chemotherapy and menses resumed years later while on tamoxifen?
If the cancer was also HER2+, would that influence your decision? 
2 Answers available
What is your strategy for a patient who develops an enlarging ipsilateral axillary lymph node shortly after undergoing mastectomy and ALND for a pT2N3 ER+/HER2+ right breast cancer?
This patient underwent mastectomy and ALND (10/28 positive lymph nodes). Immediately following axillary LN dissection (and prior to radiation) imaging...
1 Answer available
What is your strategy for ovarian suppression if unable to achieve goal estradiol levels with leuprolide 3.75mg monthly dose?
Data from the SOFT/TEXT trials showed clinical benefit in ovarian suppression + aromatase inhibition for high risk, premenopausal ...
3 Answers available
How would you approach a patient with HR+, HER2- metastatic breast cancer who is endocrine resistant, with bone marrow involvement and pancytopenia?
How would this change if the patient had metastatic HR+,HER2- breast cancer and now has symptomatic pancytopenia secondary to BM involvement after TCH...
5 Answers available
Would you consider adding neoadjuvant endocrine therapy in a patient with HR+, HER2- breast cancer who has not clinically responded to neoadjuvant chemotherapy?
She has received 4 cycles of AC with no clinical response and is now pending completion with Taxol.
1 Answer available
Would you choose neoadjuvant endocrine therapy for a low grade, node negative, ER/PR positive, breast cancer given delays in definitive surgery due to the COVID-19 pandemic?
Would your choice vary based on the patient's gender?
1 Answer available
How would you approach adjuvant therapy in a patient with HR+ breast cancer with a high RS (>25) given the current COVID-19 pandemic?
Would you consider delaying chemotherapy and proceeding only with endocrine for now?
2 Answers available
How would you treat an elderly female with metastatic HR+,HER2- breast cancer on endocrine therapy who now has progressive bone only disease?
Initially treated with anastrozole, current treatment is with fulvestrant.  
3 Answers available
How would you approach a premenopausal woman with HR+, HER2- metastatic breast and a PIK3CA mutation?
1 Answer available
How would you treat a patient with locally advanced HR+ breast cancer with contralateral axillary lymph node involvement?
No primary identified in the contralateral breast. No distant metastasis identified.
1 Answer available
How would you treat a patient with HR+,HER2- metastatic breast cancer with a gBRCA mutation who has progressed on endocrine therapy with a new pericardial effusion?
2 Answers available
How do you approach a pre-menopausal female with HR+ breast cancer with discordant IHC and OncotypeDx ER expression?
IHC: ER 70%; PR 70% OncotypeDx: ER - Negative; PR - Positive
1 Answer available
How would you approach a patient with T3 HR+,HER2- breast cancer who had no clinical improvement after ddAC?
Do you proceed with Paclitaxel or go to surgery instead?
2 Answers available
How do you approach recurrent, localized HR+, HER2- breast cancer in a patient who has progressed on exemestane (and previously on letrozole and tamoxifen)?
2 Answers available
Would you use a NTRK TKI for a patient with metastatic HR+, HER2- breast cancer with a complex NTRK3 gene re-arrangement on Foundation testing?
ie, not a classic NTRK3-ETV6 fusion.The patient has progressed through CDk4/6 inhibitors and intolerant of alpelisib, and does not want chemotherapy.&...
1 Answer available
Do you change systemic endocrine therapy for a patient who progresses only in the brain after SRS for metastatic HR+ breast cancer?
She has no other site of disease progression and has been on an aromatase inhibitor (progressed in the CNS while on a study with adjuvant abemaciclib)...
1 Answer available
How would you approach adjuvant therapy for a premenopausal female with HR+, HER2+ breast cancer with N1mic disease?
Stage T1bN1mic
2 Answers available
Would you offer neoadjuvant immunotherapy in addition to chemotherapy for locally advanced HR+ breast cancer based on the I-SPY 2 data?
2 Answers available
How would you approach a postmenopausal female with localized ER+ breast cancer on adjuvant anastrozole with a rising estradiol level?
Pre-treatment estradiol: <5 Estradiol after 1 yr: 35
3 Answers available
Would you re-introduce bisphosphonate or denosumab in a bone-only metastatic ER+ breast cancer patient with history of osteonecrosis of the jaw?
2 Answers available
Would you use neoadjuvant CDK4/6 inhibitor and AI in HR+ breast cancer based upon the randomized phase II CORALLEEN trial?
https://www.ncbi.nlm.nih.gov/pubmed/31838010
1 Answer available
In a patient with early stage HR+ breast cancer who was perimenopausal at diagnosis but intolerant of AI, would you consider extending tamoxifen beyond 10 years?
In the absence of side effects, would you be inclined to continue beyond 10 years as chemoprevention? Would you factor an intermediate/high oncotype R...
2 Answers available
What factors influence your decision regarding whether to administer a dose-dense chemotherapy regimen in the adjuvant setting to patients with hormone-receptor postive disease?
Data presented at the 2017 SABCS (abstract GS1-01) of the EBCTCG meta-analysis stating a benefit of dose-dense chemotherapy applies to ER positive and...
2 Answers available
What do you recommend for women on AI therapy who experience excessive hair loss?
2 Answers available
How would you treat a postmenopausal woman with recurrent, localized ER+,HER2- breast cancer to the contralateral breast while on AI?
4 Answers available
In a patient with HR+HER2+ early breast cancer who is receiving adjuvant T-DM1 for residual disease, do you overlap endocrine therapy with T-DM1?
2 Answers available
For premenopausal patients with early stage HR+ breast cancer for whom you are recommending tamoxifen, how do you select patients for extended endocrine therapy?
Are there clinical scenarios in which 5 years of tamoxifen alone remains sufficient?
1 Answer available
Would a low or intermediate OncoType RS affect your choice of adjuvant endocrine therapy for a premenopausal woman with high clinical risk HR+ early stage disease?
Would you offer AI + OFS or tamoxifen to a woman with a grade 3 T2N0 tumor and OncoType of 15?
3 Answers available
Would you offer additional therapy for a patient with HR+ breast cancer on AI+OS who is found to have a focus of ovarian metastasis at the time of elective BSO?
Additionally, would the finding of any mutations, such as ESR1, change your recommendation? 
2 Answers available
Does germline BRCA 1/2 mutation status impact your use of OncoType Dx for early stage ER positive breast cancers in post-menopausal women?
Would you offer adjuvant chemotherapy to a post-menopausal woman with a BRCA2 mutation and a T2N0 ER positive breast cancer with an oncotype of 12?
1 Answer available
Would you offer adjuvant HER 2 directed therapy for ER+/PR+/HER2+ pT1-T2 N0 papillary carcinoma of the breast?
It is included in favorable histologies on NCCN, but no mention of how to treat based off HER2 status.
1 Answer available
What is your preferred chemotherapy regimen for patients with peripheral neuropathy and high risk HR+/HER2- breast cancer?
1 Answer available
What factors influence whether you order OncotypeDx in HR+ node negative ILC?
1 Answer available
Does a complete pathologic response to neoadjuvant chemotherapy affect the duration of endocrine therapy/OFS that you recommend for a premenopausal patient with HR+/Her2+ breast cancer?
1 Answer available
How do you decide which patients need extended adjuvant endocrine therapy?
1 Answer available
How would you approach a patient with metastatic ER/PR+,HER2- breast cancer with linear leptomeningeal enhancement on MRI but negative CSF protein and cytology?
She had disease progression on palbociclib and letrozole. She also has a PIK3CA mutation however did not tolerate alpelisib due to Grade 3 hyperglycem...
1 Answer available
How do you approach a post-menopausal female with early stage ER+,HER2+ breast cancer s/p lumpectomy with invasive ductal histology and lymph node involvement with invasive lobular histology? 
Margins were negative and there was no evidence of LCIS or lobular component in the lumpectomy specimen. Role for possible mastectomy?
3 Answers available
What adjuvant endocrine therapy would you recommend for patients who have undergone prior gastrectomy?
More generally, do absorption issues effect the efficacy of tamoxifen and/or aromatase inhibitors?
1 Answer available
How would you approach a post-menopausal female with both a previously HR+ HER2- breast cancer and HR- HER2+ breast cancer with new brain metastasis?
How would you figure out how to treat someone with a prior localized HR+,HER2- breast cancer treated with adjuvant AC-T (5years ago) and a recent ipsi...
1 Answer available
How would you approach a young patient with ER+/Her2- bilateral breast cancer with a solitary bone metastasis?
Would you consider an aggressive approach with RT and/or surgery to the bone lesion and treat the primary as locally advanced breast cancer?
1 Answer available
How would you approach a patient with ER+,HER2- T4N0 breast cancer with chest wall involvement?
Role of neoadjuvant TC vs. anthracycline based regimen?
1 Answer available
How would you manage a postmenopausal female with a history of early stage invasive ductal ER+/HER2- breast cancer s/p mastectomy who has a local recurrence of ER+/Her2 - lobular carcinoma while on letrozole?
2 Answers available
How would you approach a patient with metastatic ER+/Her2+ who has progressed on trastuzumab/pertuzumab + tamoxifen after being in remission for 4yrs?
2 Answers available
What is optimal timing or sequencing of therapy for patients with synchronous locally advanced triple negative breast cancer and ovarian cancer with peritoneal carcinomatosis?
2 Answers available
How do you use neratinib in HR+ HER2+ patients in the adjuvant setting if patients got adjuvant T-DM1 for residual disease after neoadjuvant therapy?
Neratinib was studied following adjuvant trastuzumab. Do you extrapolate that data to give neratinib to patients who have received adjuvant T-DM1 inst...
1 Answer available
For triple positive metastatic breast cancer, is there a role for aromatase inhibitor + CDK 4/6 inhibitor with Her2 directed therapy in a patient that refuses chemotherapy?
Patient defers chemotherapy. She is currently on anastrozole/Herceptin and perjeta with a response but it is suboptimal. I would like to add a CDK 4/6...
2 Answers available
Would you change treatment for denovo stage IV breast cancer Her 2 positive, ER positive in remission now with isolated brain metastasis?
The patient received THP and now is on maintenance HP when she developed CNS disease.
3 Answers available
How would you treat a patient with a known history of ER/PR 90% and HER2 negative who develops skeletal metastatic disease on adjuvant endocrine therapy but now ER is only 2% and is PR and HER2 negative?
Initially stage 1 disease with high risk Mammaprint recurrence risk completed adjuvant chemo 15 months ago. 
1 Answer available
How would you treat a young patient with good performance status who has de novo metastatic HR+ Her2+ inflammatory breast cancer with asymptomatic leptomeningeal and CNS parenchymal disease?
1 Answer available
Can you use Oncotype for determining adjuvant therapy in a young, premenopausal woman with multifocal HR+ breast cancer s/p mastectomy with 2 positive lymph nodes?
1 Answer available
Is there a role for the neoadjuvant use of CDK 4/6 inhibitors with endocrine therapy in patients with well differentiated and/or invasive lobular histology who desire breast conservation?
The use of neoadjuvant CDK 4/6 inhibitors is not standard of care, but there are clinical trials looking at this question and patients who are chemoth...
1 Answer available
What is the role of neo-adjuvant chemotherapy in triple positive cT1c N0 breast cancer especially after recent data from KATHERINE trial?
Clinical T1c patients were included in the KATHERINE trial that often are treated with adjuvant paclitaxel and trastuzumab
1 Answer available
How do you utilize CDK 4/6 inhibitors in metastatic ER+ HER2+ breast cancer?
One such patient progressed through trastuzumab/pertuzumab/letrozole and TDM1 alone.  How would you combine ER+ approaches (eg CDK 4/6 inhibitor ...
1 Answer available
Is a tumor ever too small to send off a genomic assay like Oncotype or Mammoprint in HR positive, HER2 negative stage 1 breast cancer?
There is a gray area in clinical decision making where the practice seems to be different for borderline size tumors such as a 7 mm T1b lesion with no...
1 Answer available
Are Mammaprint and OncotypeDx as useful in stratifying risk in patients with early stage HR+, HER2 negative lobular carcinomas, as in those with ductal carcinomas?
1 Answer available
In a patient with resected ER+ HER2- breast cancer, how do you decide between TC vs ddAC-T for adjuvant chemotherapy?
Do you have a cutoff in terms of tumor size, number of LN, Oncotype score, etc that makes you choose lower vs higher intensity chemo?
1 Answer available
What would you choose as second-line therapy in patients with ER/PR-positive, HER2-negative metastatic breast cancer progressing on first-line CDK 4/6 inhibitor/AI combination?
Assume good compliance with oral therapy, equivalent access to either agent, no contraindictions to either therapy, and absence of any visceral crisis...
3 Answers available


Papers discussed in this category

The New England journal of medicine, 2018-07-12
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
Clinical breast cancer, 2010-12-01
Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-08-10
Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).
Lancet (London, England), 2014-03-22
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
The New England journal of medicine, 2011-06-23
Exemestane for breast-cancer prevention in postmenopausal women.
Journal of the National Cancer Institute, 2005-09-07
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
The New England journal of medicine, 2016-07-21
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.
European radiology, 2022 May 07
Background parenchymal enhancement in contrast-enhanced MR imaging suggests systemic effects of intrauterine contraceptive devices.
The Cochrane database of systematic reviews, 2020 Dec 21
Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
N Engl J Med,
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-09-01
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research, 2017 May 22
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR/HER2 Metastatic Breast Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 May 19
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial.
Lancet (London, England), 2016-12-17
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Breast cancer research and treatment, 2014-01
A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure.
Lancet (London, England), 2013-03-09
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-04-20
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen.
Journal of the National Cancer Institute, 2013-07-17
Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-09-01
Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline.
The Lancet. Oncology, 2019-01
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-05-10
Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.
J. Clin. Oncol., 2019 Oct 16
Improving Adjuvant Endocrine Treatment Tailoring in Premenopausal Women With Hormone Receptor–Positive Breast Cancer
Cancer, 2010-11-15
Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers.
The breast journal, 2017-11
An Analysis of Oncotype DX Recurrence Scores and Clinicopathologic Characteristics in Invasive Lobular Breast Cancer.
The Lancet. Oncology, 2017-12
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
N. Engl. J. Med., 2017-07-13
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
Lancet Oncol., 2016-06-01
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Annals of oncology : official journal of the European Society for Medical Oncology, 2013-09
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).
JAMA Oncol,
Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.
NPJ Breast Cancer, 2021 Nov 11
Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness.
J Clin Oncol, 2020 Feb 25
TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline Carriers With HER2-Negative Breast Cancer (the INFORM trial).
Mol Oncol,
The MINDACT trial: the first prospective clinical validation of a genomic tool.
JAMA,
Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results.
N Engl J Med, 2015 Jan 8
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.
Lancet Oncol., 2017 Feb 24
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.
Eur. J. Cancer, 2017 May 03
Characterisation of multifocal breast cancer using the 70-gene signature in clinical low-risk patients enrolled in the EORTC 10041/BIG 03-04 MINDACT trial.
The New England journal of medicine, 2012-01-12
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
J. Clin. Oncol., 2018 Dec 06
Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.
The New England journal of medicine, 2016-08-25
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
Journal of the National Comprehensive Cancer Network : JNCCN, 2017-04
The 21-Gene Recurrence Score Assay for Node-Positive, Early-Stage Breast Cancer and Impact of RxPONDER Trial on Chemotherapy Decision-Making: Have Clinicians Already Decided?
Journal of neurosurgery, 2019-02-08
Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases.
Breast cancer research and treatment, 2018-06
Intrathecal trastuzumab in the management of HER2+ breast leptomeningeal disease: a single institution experience.
Trials, 2013 Aug 19
WSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial.
Ann. Oncol., 2012 Jun 06
Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study.
Cancer,
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Annals of surgical oncology, 2014-10
Chemosensitivity predicted by BluePrint 80-gene functional subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST).
N. Engl. J. Med.,
Pembrolizumab for Early Triple-Negative Breast Cancer.
Ann Surg Oncol, 2022 Apr 04
Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer.
The New England journal of medicine, 2019-02-14
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
Oncotarget,
Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-04-10
Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial.
The New England journal of medicine, 2012-08-02
Combination anastrozole and fulvestrant in metastatic breast cancer.
The Lancet. Oncology, 2014-02
Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial.
Annals of surgical oncology, 2018-10
Randomized Trial Comparing Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at Presentation: Protocol MF07-01.
Annals of surgery, 2019-03
Surgical Resection of the Primary Tumor in Women With De Novo Stage IV Breast Cancer: Contemporary Practice Patterns and Survival Analysis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-08-01
Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
N Engl J Med, 2011 Oct 6
Adjuvant trastuzumab in HER2-positive breast cancer.
Lancet (London, England), 2012-02-04
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.
Breast cancer research and treatment, 2008-01
MRI compared to conventional diagnostic work-up in the detection and evaluation of invasive lobular carcinoma of the breast: a review of existing literature.
Cancer, 1998-02-15
Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results.
Cancer, 2010-04-15
Route of intracerebrospinal fluid chemotherapy administration and efficacy of therapy in neoplastic meningitis.
N. Engl. J. Med.,
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.
Breast cancer research and treatment, 2011-07
Prospective randomized trial of 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus paclitaxel and FAC (TFAC) in patients with operable breast cancer: impact of taxane chemotherapy on locoregional control.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-05-01
Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005-06-01
Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.
N Engl J Med, 2005 Jun 2
Adjuvant docetaxel for node-positive breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-10-10
Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial.
N Engl J Med,
Weekly paclitaxel in the adjuvant treatment of breast cancer.
Cancer, 2016-04-15
Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status.
The New England journal of medicine, 2019-06-20
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.
Ann. Oncol.,
Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2017-09
A prospective study of aromatase inhibitor therapy initiation and self-reported side effects.
Springerplus, 2016 May 10
Management of hair loss associated with endocrine therapy in patients with breast cancer: an overview.
JAMA dermatology, 2018-06-01
Endocrine Therapy-Induced Alopecia in Patients With Breast Cancer.
The New England journal of medicine, 2014-07-10
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-05-10
Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer.
The American journal of surgical pathology, 2017-11
Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.
N. Engl. J. Med.,
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
Oncologist, 2020 Jul 03
Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003-11-15
The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
N. Engl. J. Med., 2017 Jun 04
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-08-10
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
JAMA Oncol, 2019 Sep 30
Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.
JAMA,
Coronavirus Disease 2019 (COVID-19) in Italy.
N Engl J Med, 2020 Mar 27
Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington.
J. Clin. Oncol., 2019 Jul 24
Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial.
Anticancer Res.,
Symptomatic bone marrow involvement in breast cancer--clinical presentation, treatment, and prognosis: a single institution review of 22 cases.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-07-01
Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.
The New England journal of medicine, 2018-07-12
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
Lancet Oncol., 2018 Nov 06
Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
J. Clin. Oncol., 2019 Oct 16
Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT.
Breast Cancer Res. Treat., 2006 May 11
Plasma levels of tamoxifen, N-desmethyl tamoxifen and anastrozole in a patient with metastatic breast cancer and chronic hemodialysis.
Lancet Oncol., 2009 Nov 10
Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial.
J Clin Oncol, 2020 Apr 10
Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial.
Breast cancer research and treatment, 2014-11
Impact of estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) co-expression on breast cancer disease characteristics: implications for tumor biology and research.
The Lancet. Oncology, 2016-03
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Mol Clin Oncol, 2019 Nov 29
Male patient with metastatic stage IV breast cancer achieves complete remission on second line Abemaciclib, Fulvestrant and Leuprolide: A case report.
Clin. Cancer Res., 2019 Oct 24
FDA Approval Summary: Palbociclib for Male Patients with Metastatic Breast Cancer.
The American journal of surgical pathology, 2006-06
An analysis of breast cancer risk in women with single, multiple, and atypical papilloma.
J Clin Oncol, 2019 Apr 11
Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia.
Cancer Treat. Rev., 2012 Nov 28
Chemotherapy, targeted agents, antiemetics and growth-factors in human milk: how should we counsel cancer patients about breastfeeding?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-04-01
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
Cancer, 2016-12-01
Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort.
N. Engl. J. Med.,
Alpelisib for -Mutated, Hormone Receptor-Positive Advanced Breast Cancer.
The Lancet. Oncology, 2014-06
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.
The New England journal of medicine, 2012-11-08
Trastuzumab emtansine for HER2-positive advanced breast cancer.
N. Engl. J. Med., 2019 Dec 11
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
Lancet Oncol., 2020 Mar 12
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
J. Clin. Oncol., 2009 Sep 28
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.
Lancet Oncol, 2020 Apr 27
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
Journal of the National Cancer Institute, 2005-11-16
Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-05-10
Molecular Characterization and Mortality From Breast Cancer in Men.
Cancer, 2020 Jun 10
Propensity score analysis of the prognostic value of genomic assays for breast cancer in diverse populations using the National Cancer Data Base.
Journal of the National Cancer Institute, 1997-11-19
Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.
Journal of surgical oncology, 2017-06
Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial.
Breast cancer research and treatment, 2015-11
A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response with the 21-gene recurrence score.
Breast Cancer Res Treat, 2020 May 20
EndoPredict in early hormone receptor-positive, HER2-negative breast cancer.
Lancet Oncol., 2014-06-01
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.
The Lancet. Oncology, 2018-04
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Pathol Oncol Res, 2017 Sep 11
Re-Appraisal of Estrogen Receptor Negative/Progesterone Receptor Positive (ER-/PR+) Breast Cancer Phenotype: True Subtype or Technical Artefact?
J Clin Oncol, 2020 Jan 13
Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update.
NPJ Breast Cancer,
Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry.
Breast cancer research : BCR, 2004
A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment.
Lancet Oncol., 2014-11-01
Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-08-01
Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-08-01
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx.
Breast cancer research and treatment, 2018-09
Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy.
J. Clin. Oncol., 2020 Sep 20
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).
Breast J, 2019 Jul 04
Ovarian remnant syndrome in an aromatase inhibitor-treated patient with BRCA2 mutation following bilateral oophorectomy.
J Clin Oncol, 2020 Oct 29
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.
Breast cancer research and treatment, 2011-10
HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis.
J. Clin. Oncol., 2018 May 30
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.
Cancer Treat Rev, 2013 Jun 10
HER2 discordance between primary and metastatic breast cancer: assessing the clinical impact.
Clin Cancer Res, 2019 Sep 12
Long-Term Survival Analysis of Adjuvant Chemotherapy with or without Trastuzumab in Patients with T1, Node-Negative HER2-Positive Breast Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research, 2018-12-01
Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel.
Cancer, 2010-05-15
Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer.
Circulation, 2020 Feb 17
Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study.
J Clin Oncol, 2018 Aug 14
First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial.
J Clin Oncol, 2020 Sep 16
Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-12-01
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-07-10
Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-07-10
Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-09-10
Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update.
Breast, 2011 Sep 08
Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial.
Sci Rep, 2019 Dec 02
Real-world Treatment Patterns and Outcomes in HR+/HER2+ Metastatic Breast Cancer Patients: A National Cancer Database Analysis.
Annals of oncology : official journal of the European Society for Medical Oncology, 2005-08
Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer.
J Clin Oncol, 2020 Oct 27
Molecular Drivers of Onco DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study.
Annals of Oncology, 2021 Sep 29
Adjuvant Abemaciclib Combined With Endocrine Therapy for High-Risk Early Breast Cancer: Updated Efficacy and Ki-67 Analysis From the monarchE Study.
Cancer Manag Res, 2012 Jun 13
Malignant bowel obstruction in advanced cancer patients: epidemiology, management, and factors influencing spontaneous resolution.
Ann Oncol, 2007 Feb 13
Pattern and prognostic factors in patients with malignant ascites: a retrospective study.
J Clin Oncol, 2021 Feb 04
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.
Clin Cancer Res, 2020 Jul 21
A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer.
NPJ breast cancer, 2023 Oct 23
Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis.
Neuro-oncology, 2023 Jan 05
Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial.
JAMA, 2011-02-09
Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial.
JAMA oncology, 2017-11-01
Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades.
J Natl Cancer Inst, 2011 Jul 09
Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.
Br J Clin Pharmacol, 2020 Jun 02
Effect of low-dose aspirin on health outcomes: An umbrella review of systematic reviews and meta-analyses.
Clin Breast Cancer, 2020 Oct 06
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.
Clin Cancer Res, 2017 Mar 07
NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.
Lancet Oncol, 2019 Dec 11
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
Ann Oncol,
Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer.
Ann Oncol, 2022 Mar 23
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study.
Journal of the National Cancer Institute, 2011-11-16
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.
Archives of pathology & laboratory medicine, 2016-01
Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical Trial.
Lancet Oncol,
Ki67 in breast cancer: prognostic and predictive potential.
J Clin Oncol, 2009 Apr 20
Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer.
Clin Cancer Res,
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
N Engl J Med, 2021 Jun 03
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
J Natl Compr Canc Netw, 2021 Mar 24
Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience.
J Clin Oncol, 2022 May 18
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.
Annals of oncology : official journal of the European Society for Medical Oncology, 2020 Nov 25
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1.
The New England journal of medicine, 2023 Jun 01
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
The Lancet. Oncology, 2022 Sep 29
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.
Breast Cancer Res Treat, 2018 Jul 04
Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis.
Eur J Haematol, 2021 Feb 18
CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real-world practice.
Cancer Sci,
Abemaciclib induces atypical cell death in cancer cells characterized by formation of cytoplasmic vacuoles derived from lysosomes.
Oncotarget, 2017 May 10
Preclinical characterization of abemaciclib in hormone receptor positive breast cancer.
Breast Cancer Res Treat, 2020 Sep 10
Effect of delays in initiation of adjuvant endocrine therapy on survival among women with breast cancer.
Lancet Oncol, 2022 Dec 06
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.
J Clin Oncol, 2011 Oct 31
Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-05-10
Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer.
Lancet, 2019 Dec 12
Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial.
Lancet (London, England), 2016-02-27
Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
N Engl J Med, 2021 Dec 01
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
N Engl J Med,
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
N Engl J Med, 2022 Jun 05
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Int J Mol Sci, 2020 Sep 03
Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis.
J Clin Oncol, 2022 Jan 07
Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108).
Ann Surg,
Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012-04-20
Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-12-10
Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance).
Breast Cancer Res, 2021 Aug 23
Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.
The New England journal of medicine, 2016-11-17
Palbociclib and Letrozole in Advanced Breast Cancer.
Clin Cancer Res, 2022 Mar 01
Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial.
Annals of oncology : official journal of the European Society for Medical Oncology, 2022 Oct 10
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
Curr Probl Cancer, 2016 Mar - Aug
Endocrine therapy and strategies to overcome therapeutic resistance in breast cancer.
Journal of the National Cancer Institute, 2000-04-05
Tumor characteristics and clinical outcome of elderly women with breast cancer.
Breast cancer research : BCR, 2018-10-19
Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial.
Breast Care (Basel), 2019 Nov 26
Ribociclib in Breast Cancer Brain Metastases: A Case Report.
Cancer Chemother Pharmacol, 2019 May 11
CNS penetration of the CDK4/6 inhibitor ribociclib in non-tumor bearing mice and mice bearing pediatric brain tumors.
Front Oncol, 2020 May 29
Lynch Syndrome Germline Mutations in Breast Cancer: Next Generation Sequencing Case-Control Study of 1,263 Participants.
Cancer Cell Int, 2021 May 17
Mismatch repair-deficient hormone receptor-positive breast cancers: Biology and pathological characterization.
Ann Gastroenterol, 2020 Jan-Feb
Clinical characteristics of colitis induced by taxane-based chemotherapy.
BMC Cancer, 2019 Oct 21
Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis.
JAMA Oncol, 2021 Sep 01
Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial.
Clin Cancer Res, 2021 Feb 19
Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease.
Clin Cancer Res, 2022 Feb 15
Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002).
Clin Cancer Res, 2020 Nov 18
Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I-III Triple-negative Breast Cancer (NeoSTOP).
Lancet, 2023 Apr 15
Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.
J Natl Cancer Inst, 2007 Dec 25
HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
Br J Cancer, 2022 Feb 22
The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer-a pooled analysis of the randomised clinical trials PlanB and SUCCESS C.
JAMA Oncol, 2020 Aug 13
Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.
Annals of oncology : official journal of the European Society for Medical Oncology, 2014-05
Which threshold for ER positivity? a retrospective study based on 9639 patients.
J Clin Pathol, 2016 Sep 09
Clinicopathological characteristics of oestrogen receptor negative, progesterone receptor positive breast cancers: re-evaluating subsets within this group.
Breast Cancer, 2018 Jul 31
Oestrogen receptor-negative/progesterone receptor-positive phenotype of invasive breast carcinoma in Japan: re-evaluated using immunohistochemical staining.
Annals of oncology : official journal of the European Society for Medical Oncology, 2003 Aug
Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation.
Helvetica chirurgica acta, 1989 Apr
Local recurrence after breast-conserving surgery and radiotherapy.
Annals of surgical oncology, 2012 May 23
Repeating conservative surgery after ipsilateral breast tumor reappearance: criteria for selecting the best candidates.
JAMA, 2021 Apr 06
Trends in Age at Natural Menopause and Reproductive Life Span Among US Women, 1959-2018.
Breast cancer research and treatment, 2023 Jun 15
Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021 Jan 29
Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer.
Ther Adv Med Oncol, 2022
Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role.
Annals of oncology : official journal of the European Society for Medical Oncology, 2019 Dec 01
Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors.
Breast cancer research and treatment, 2020 Aug 10
Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway.
JCO precision oncology, 2022 Mar
Cyclin-Dependent Kinase 4/6 Inhibitor Outcomes in Patients With Advanced Breast Cancer Carrying Germline Pathogenic Variants in DNA Repair-Related Genes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-09-10
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.
The oncologist, 2022 Mar 28
Alpelisib Plus Fulvestrant or Letrozole Demonstrates Sustained Benefits Across Subgroups of Patients with PIK3CA-Mutated HR+/HER2- Advanced Breast Cancer.
The Journal of clinical investigation, 2010-07
Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer.
Science translational medicine, 2015-04-15
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.
Cancer discovery, 2020 May 13
The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research, 2022 Mar 01
Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer.
Molecular cancer therapeutics, 2012 Jan 31
Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.
Signal transduction and targeted therapy, 2021 Dec 16
Targeting PI3K/Akt signal transduction for cancer therapy.
International journal of molecular sciences, 2021 Dec 16
Targeting AKT in ER-Positive HER2-Negative Metastatic Breast Cancer: From Molecular Promises to Real Life Pitfalls?

Related Topics

Copyright © 2024 theMednet
All Rights Reserved.